8-K: Align Technology Reports Strong Q4 and Fiscal Year 2023 Results, Unveils New iTero Lumina Scanner

Align Technology announced better-than-expected fourth quarter and full year 2023 financial results, highlighted by the launch of the next-generation iTero Lumina intraoral scanner.

Summary

• Align Technology reported a 6.1% year-over-year increase in total revenue for the fourth quarter of 2023, reaching $956.7 million.
• Full year 2023 total revenue reached $3.9 billion, a 3.4% increase compared to 2022.
• Clear Aligner revenues for 2023 were $3.2 billion, while Systems and Services revenues totaled $662.9 million.
• The company achieved a 2023 operating margin of 16.7% and a non-GAAP operating margin of 21.4%.
• Diluted net income per share for 2023 was $5.81, and non-GAAP diluted net income per share was $8.61.
• Align repurchased $600 million of common stock in 2023.
• The company launched the iTero Lumina intraoral scanner, featuring a 3X wider field of capture and a 50% smaller wand.
• Align has reached 17 million Invisalign patients, 4 million Vivera retainer cases, and sold over 100 thousand iTero scanners.
• Q4 2023 clear aligner volume was down 0.6% year-over-year.
• Q4 2023 net income was $124.0 million, or $1.64 per diluted share, and non-GAAP net income was $183.5 million, or $2.42 per diluted share.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, a significant product launch, and a clear growth strategy. While there are some challenges, the overall tone is optimistic and suggests a company in a strong position.

Positives

• The company exceeded expectations for both revenue and earnings in Q4 2023.
• There was a sequential increase in clear aligner volume for adults and non-comprehensive cases.
• The EMEA and APAC regions showed growth in revenue.
• The launch of the iTero Lumina scanner is expected to drive future growth and efficiency.
• The company has a strong track record of innovation and product development.
• Align has a large untapped market opportunity of 22 million annual orthodontic case starts.
• The company has a $650 million remaining available for repurchase of common stock under the stock repurchase program.
• The company has a strong cash position with $980.8 million in cash, cash equivalents and short-term and long-term marketable securities.

Negatives

• Q4 2023 clear aligner volume was down 0.6% year-over-year.
• 2023 revenues were unfavorably impacted by foreign exchange of approximately $36.3 million compared to 2022.
• Q4 2023 revenues were unfavorably impacted by foreign exchange of approximately $12.8 million sequentially.
• The company incurred $14.0 million of restructuring and other charges in Q4 2023.
• Cash, cash equivalents and short-term and long-term marketable securities decreased from over $1.3 billion as of September 30, 2023 to $980.8 million as of December 31, 2023.

Risks

• Macroeconomic conditions, including inflation and currency fluctuations, could impact the company's performance.
• Changes in consumer spending habits and purchasing behavior could affect demand for Align's products.
• Competition from existing and new competitors could impact market share.
• Supply chain disruptions and increased costs could affect the company's ability to manufacture and distribute products.
• The company faces risks related to foreign operations, political instability, and military conflicts.
• The company's ability to protect and enforce its intellectual property rights is crucial.
• The company's ability to sustain or increase profitability or revenue growth in future periods while controlling expenses is a risk.
• The company faces risks related to the compromise of its systems or networks, including customer and patient data.

Future Outlook

Align expects Q1 2024 worldwide revenues to be in the range of $960M to $980M, and full year 2024 total revenues to be up mid-single digits over 2023. They also anticipate slight increases in clear aligner ASPs and operating margins for 2024.

Management Comments

• Joe Hogan, President and CEO, stated that he was pleased to report fourth quarter results with better-than-expected revenues and earnings.
• Joe Hogan highlighted the launch of the iTero Lumina scanner as a breakthrough technology.
• John Morici, CFO and EVP Global Finance, expressed pride in the company's execution of its product roadmap and innovation pipeline.
• John Morici believes that the next wave of innovation will further differentiate Align and allow them to increase their share of the large untapped market opportunity.

Industry Context

This announcement highlights Align's continued leadership in the digital orthodontics market. The launch of the iTero Lumina scanner positions them to further innovate and capture market share. The company's focus on international expansion and product development aligns with broader trends in the dental industry towards digital solutions and increased patient access.

Comparison to Industry Standards

• Align's revenue growth of 3.4% for 2023 is moderate compared to some high-growth tech companies, but is solid for a medical device company in a competitive market.
• The operating margin of 16.7% is healthy, but the non-GAAP operating margin of 21.4% is more impressive, indicating strong underlying profitability when excluding certain non-recurring items.
• Competitors like Straumann and Dentsply Sirona also operate in the dental technology space, but Align's focus on clear aligners and digital workflows gives them a unique position.
• The launch of the iTero Lumina scanner is a significant product development that could give Align a competitive edge over companies using older scanning technology.
• Align's stock repurchase program is a common practice among mature companies, but the $600 million repurchase in 2023 is a substantial amount, indicating confidence in the company's future prospects.

Management Changes

Stakeholder Impact

• Shareholders will benefit from the stock repurchase program and the company's positive financial performance.
• Employees will benefit from the company's growth and innovation.
• Customers will benefit from the new iTero Lumina scanner and other product developments.
• Suppliers will benefit from the company's continued growth and demand for its products.
• Creditors will benefit from the company's strong financial position.

Next Steps

• The company will continue to focus on international expansion, patient demand, orthodontist utilization, and GP dentist treatment.
• Align will continue to invest in product development and innovation.
• The company will continue to execute its stock repurchase program.
• Align will host a conference call on January 31, 2024, to discuss the results and outlook.

Key Dates

Keywords

Invisalign, iTero, clear aligners, intraoral scanner, digital orthodontics, dental, medical device, revenue, operating margin, stock repurchase